Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Eli Lilly and Company    LLY

ELI LILLY AND COMPANY

(LLY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
  • Eli Lilly And Company accounts for 5.72 % of our USA Portfolio. A trade is currently open since 06/30/2020 with a purchase price of $ 161.35. Discover the other 19 stocks of the USA portfolio managed by the MarketScreener portfolio management team.
Strengths
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
  • Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The stock is in a well-established, long-term rising trend above the technical support level at 156.88 USD
Weaknesses
  • Stock prices approach a strong long-term resistance in weekly data at USD 216.96.
  • Technically, the stock approaches a strong medium-term resistance at USD 214.26.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
ELI LILLY AND COMPANY19.20%182 459
JOHNSON & JOHNSON3.18%427 472
ROCHE HOLDING AG3.56%308 129
NOVARTIS AG2.82%219 666
MERCK & CO., INC.0.81%208 627
PFIZER INC.-0.84%202 881
ABBVIE INC.5.11%198 828
NOVO NORDISK A/S3.95%166 737
BRISTOL-MYERS SQUIBB COMPAN..6.80%149 709
AMGEN INC.9.76%146 916
ASTRAZENECA PLC4.38%136 895
SANOFI4.64%125 166
GLAXOSMITHKLINE PLC2.82%93 928
CHUGAI PHARMACEUTICAL CO., ..2.85%88 417
JIANGSU HENGRUI MEDICINE CO..-2.97%87 016
DAIICHI SANKYO COMPANY, LIM..2.09%67 211
More Results
Financials (USD)
Sales 2020 24 407 M - -
Net income 2020 5 802 M - -
Net Debt 2020 11 301 M - -
P/E ratio 2020 31,8x
Yield 2020 1,47%
Capitalization 183 B 183 B -
EV / Sales 2020 7,98x
EV / Sales 2021 7,01x
Nbr of Employees 33 625
Free-Float 99,8%
Upcoming event on ELI LILLY AND COMPANY
Notations Surperformance©
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes